Clinical Trial Update: A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, and clinical response of SAR441566 versus placebo in mild to moderate psoriasis. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• SAR441566 (SAR441566)

Snippet

Sponsor: Sanofi | Conditions: Psoriasis | Phase 1 | Status: COMPLETED